Collegium Pharmaceutical/COLL

$35.62

-0.89%
-
1D1W1MYTD1YMAX

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

Ticker

COLL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joseph Ciaffoni

Employees

197

Headquarters

Stoughton, United States

COLL Metrics

BasicAdvanced
$1.14B
Market cap
39.38
P/E ratio
$0.88
EPS
1.07
Beta
-
Dividend rate
$1.14B
1.06971
$40.95
$20.83
404.37K
1.174
1.103
247.575
341.384
7.58
2.59%
4.16%
24.68%
6.75%
39.377
2.005
5.665
4.142
22.17%
218.91%
22.28%
14.83%

What the Analysts think about COLL

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 4 analysts.
12.3% upside
High $41.00
Low $39.00
$35.62
Current price
$40.00
Average price target

COLL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
21.3% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$149.7M
9.51%
Net income
$31.9M
54.85%
Profit margin
21.3%
41.43%

COLL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 24.24%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.51
$0.34
$0.53
$0.82
-
Expected
$0.31
$0.29
$0.52
$0.66
$0.75
Surprise
-262.42%
18.26%
2.58%
24.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Collegium Pharmaceutical stock?

Collegium Pharmaceutical (COLL) has a market cap of $1.14B as of April 25, 2024.

What is the P/E ratio for Collegium Pharmaceutical stock?

The price to earnings (P/E) ratio for Collegium Pharmaceutical (COLL) stock is 39.38 as of April 25, 2024.

Does Collegium Pharmaceutical stock pay dividends?

No, Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders as of April 25, 2024.

When is the next Collegium Pharmaceutical dividend payment date?

Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders.

What is the beta indicator for Collegium Pharmaceutical?

Collegium Pharmaceutical (COLL) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Collegium Pharmaceutical stock price target?

The target price for Collegium Pharmaceutical (COLL) stock is $40, which is 12.74% above the current price of $35.48. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Collegium Pharmaceutical stock

Buy or sell Collegium Pharmaceutical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing